Overall rank by patents
#25,696
Across all tracked assignees
USPTO PatentsView assignee record - 10 granted patents across 6 technology areas, active 2020–2025. Filing-trend and competitive-moat analysis cross-referenced to USPTO Patent Public Search. Primary class: A43B (CHARACTERISTIC FEATURES OF FOOTWEAR; PARTS OF FOOTWEAR).
The verdict
APOS holds 10 US patents across 6 technology areas, rank #25,696 of 50,000 tracked assignees.
APOS Medical Assets Ltd. has been granted 10 US utility patents between 2020 and 2025, placing APOS Medical Assets Ltd. at rank #25,696 across all assignees tracked by PlainPatent. This portfolio spans 6 distinct Cooperative Patent Classification (CPC) subclasses, averaging 7.5 claims per patent with primary concentration in A43B (CHARACTERISTIC FEATURES OF FOOTWEAR; PARTS OF FOOTWEAR). As a Foreign Corporation, APOS Medical Assets Ltd. is one of the more focused assignees in the PatentsView dataset. By volume, APOS sits between Aoptix Technologies, Inc. (10 patents, rank #25,692) and Aquahydrex PTY Ltd (10 patents, rank #25,700) - the closest US assignees by grant volume. The composite Innovation Score of 41.4/100 blends portfolio volume, filing velocity, technology breadth, and claim depth into a single comparable measure drawn directly from USPTO PatentsView records.
Filing cadence tells the strategic story. Historical data spans 2020 through 2025, with 10 total grants over that period. Velocity comparisons require five years of historical filings to calibrate. The Foreign Corporation classification further shapes interpretation, since corporate, government, and individual filers pursue patents for materially different reasons.
Claim depth and technology breadth together indicate competitive posture. APOS Medical Assets Ltd.'s 7.5 average claims per patent suggests focused, narrowly drawn claims typical of single-invention filings, while concentration in 6 subclasses points to a focused technical program. Combined with portfolio volume, these signals let analysts, investors, and licensing professionals benchmark APOS Medical Assets Ltd. against peers pursuing similar technology classes.
Granted US patents 2015–2025 versus its nearest-ranked assignees by volume, this company marked ◀
AOptix Technologies, Inc.
10 patents
APANA Inc.
10 patents
APEM
10 patents
APHP (ASSISTANCE PUBLIQUE HÔPITAUX DE PARIS)
10 patents
APPLIED VISION CORPORATION
10 patents
APTON BIOSYSTEMS, INC.
10 patents
AQUA BIO TECHNOLOGY ASA
10 patents
AQUAHYDREX PTY LTD
10 patents
APOS MEDICAL ASSETS LTD.
10 patents
What this shows APOS holds 10 patents at rank #25,696, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.
APOS's Innovation Score vs. every tracked assignee
Composite of portfolio volume, filing velocity, technology breadth, and claim depth (0–100)
41 Top 33% higher than 67% of 50,000 US assignees
Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.
Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025
Teal-shaded recent years (2020–present) versus the 2020–2019 baseline. Full figures in the table below.
| Year | Patents Granted | Share of Period |
|---|---|---|
| 2020 | 2 | 20.0% |
| 2022 | 3 | 30.0% |
| 2024 | 4 | 40.0% |
| 2025 | 1 | 10.0% |
Top 6 of 6 technology areas
Overall rank by patents
#25,696
Across all tracked assignees
41.4 out of 100
How to use this portfolio
APOS's 10 grants land it in the top 33% by Innovation Score, but volume alone doesn't tell you where the strength sits.
Patent counts and the Innovation Score measure patenting activity, not commercial success or the legal strength of any patent. Many patents are filed defensively. Verify the status of an individual patent against official USPTO records.
Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.